博晖创新(300318) - 2018 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2018 reached ¥128,637,899.74, representing a 54.02% increase compared to ¥83,520,656.10 in the same period last year[7] - Net profit attributable to shareholders was ¥7,530,601.21, a significant increase of 439.86% from ¥1,394,918.33 year-over-year[7] - The net profit after deducting non-recurring gains and losses was ¥7,251,785.49, up 550.05% from ¥1,115,578.70 in the previous year[7] - Basic and diluted earnings per share were both ¥0.0092, reflecting a 441.18% increase compared to ¥0.0017 in the same period last year[7] - The company's operating revenue for the reporting period was RMB 128.64 million, representing a year-on-year increase of 54.02%[24] - Net profit for Q1 2018 was ¥8,326,652.67, compared to ¥1,836,724.71 in Q1 2017, marking a growth of 353%[45] - The total profit for Q1 2018 was CNY 9,299,498.35, an increase from CNY 8,569,013.21 in the previous year, representing a growth of approximately 8.5%[49] - The net profit for Q1 2018 reached CNY 8,137,061.06, compared to CNY 7,497,886.56 in Q1 2017, indicating a year-over-year increase of about 8.6%[49] - Basic and diluted earnings per share for Q1 2018 were both CNY 0.0100, up from CNY 0.0092 in the same period last year, reflecting an increase of approximately 8.7%[49] Assets and Liabilities - Total assets decreased by 11.77% to ¥2,415,168,439.23 from ¥2,737,468,431.65 at the end of the previous year[7] - Net assets attributable to shareholders fell by 25.59% to ¥1,096,933,736.16 from ¥1,474,242,334.41 at the end of the previous year[7] - The company's total assets increased to ¥2,337,954,561.93 from ¥2,176,134,523.73, representing an increase of 7.4%[42] - Total liabilities rose to ¥828,616,196.76, up from ¥675,232,969.62, indicating a growth of 22.7%[42] - Total current liabilities increased from ¥966,929,640.32 to ¥1,096,195,557.38, reflecting a rise of about 13.4%[38] - The total equity attributable to shareholders decreased from ¥1,474,242,334.41 to ¥1,096,933,736.16, a decline of about 25.6%[39] Cash Flow - The company reported a net cash flow from operating activities of -¥36,828,618.07, a slight decline of 4.52% compared to -¥35,235,722.45 in the previous year[7] - Cash inflow from operating activities totaled CNY 121,804,225.06, compared to CNY 103,511,956.17 in the previous year, marking an increase of about 17.7%[51] - Cash outflow from operating activities was CNY 158,632,843.13, up from CNY 138,747,678.62, resulting in a net cash flow from operating activities of CNY -36,828,618.07, slightly worse than CNY -35,235,722.45 in the previous year[52] - Cash inflow from financing activities was CNY 154,586,408.00, down from CNY 201,540,000.00, indicating a decrease of approximately 23.3%[53] - The net cash flow from financing activities was CNY 35,145,857.50, compared to CNY 84,703,847.26 in the previous year, showing a decline of about 58.5%[53] - The ending cash and cash equivalents balance was CNY 56,392,293.50, down from CNY 67,278,025.64 at the beginning of the period, reflecting a decrease of approximately 16.5%[53] Expenses and Investments - The company's financial expenses increased by 80.89% year-on-year, primarily due to an increase in bank borrowings[24] - The company's sales expenses increased by 42.27% year-on-year, reflecting ongoing investments in new product and blood product market expansion[24] - The company's tax expenses increased by 624.93% year-on-year, primarily due to the utilization of previously deductible losses against current profits[25] - Operating costs for the same period were ¥118,503,228.43, up from ¥81,878,930.00, reflecting a rise of approximately 44.7%[44] - The company reported a cash outflow from investment activities of CNY 14,118,032.00, compared to CNY 55,407,312.73 in the previous year, indicating a significant reduction in investment spending[52] Strategic Focus - The company is focusing on enhancing its quality management system to mitigate risks associated with product safety in the biopharmaceutical sector[10] - The company plans to increase investment in product research and development to support the establishment of new plasma collection stations amid regulatory uncertainties[12] - The company aims to strengthen project management and introduce advanced tools to improve the success rate of new product development in the medical device sector[15] Shareholder Information - The company received compensation for 29.72% equity in Hebei Daan, resulting in an increase in its shareholding and a corresponding investment income of RMB 352.20 million[22] - The company's capital reserve decreased by 99.91% compared to the beginning of the year, due to adjustments related to the acquisition of Hebei Daan shares[23] - The company's cash and cash equivalents were impacted by a foreign exchange loss of RMB 380,300, a decrease of 179.52% year-on-year[26] - Accounts receivable increased from ¥86,836,674.49 to ¥95,222,585.48, representing an increase of about 10.5%[36] - Inventory rose from ¥560,156,664.36 to ¥585,091,810.34, indicating an increase of approximately 4.4%[36] - The company's short-term borrowings decreased from ¥201,680,000.00 to ¥151,726,408.00, a decrease of approximately 24.7%[38] - Other payables increased from ¥560,320,599.28 to ¥643,106,233.23, representing an increase of about 14.7%[38] - The company's non-current liabilities remained relatively stable, with a slight decrease from ¥156,844,772.01 to ¥156,112,106.91[38] - The company's retained earnings decreased from ¥299,122,965.40 to ¥295,032,404.99, a decline of about 1.3%[39] Audit Information - The company did not conduct an audit for the Q1 2018 report[57]